Detalles de la búsqueda
1.
Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions.
Blood;
139(3): 413-423, 2022 01 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-34570876
2.
Real-world treatment patterns, survival, health resource use and costs among Medicare beneficiaries with diffuse large B-cell lymphoma.
Future Oncol;
20(6): 317-328, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-38050764
3.
Cost-Effectiveness Analyses in AML: What Have We Learned, How Should This Impact Patient Care, and What Needs to Be Done in the Future?
J Natl Compr Canc Netw;
21(5): 522-528, 2023 04 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37037494
4.
DTRMWXHS-12, a novel Bruton tyrosine kinase inhibitor, in combination with everolimus and pomalidomide in patients with relapsed/refractory lymphomas: An open-label, multicenter, phase 1a/1b study.
Am J Hematol;
98(5): 739-749, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-36810799
5.
Cost-effectiveness of first-line vs third-line ibrutinib in patients with untreated chronic lymphocytic leukemia.
Blood;
136(17): 1946-1955, 2020 10 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-32518952
6.
Outcomes of COVID-19 in patients with CLL: a multicenter international experience.
Blood;
136(10): 1134-1143, 2020 09 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-32688395
7.
Challenges and Opportunities in the Management of Diffuse Large B-Cell Lymphoma in Older Patients.
Oncologist;
26(2): 120-132, 2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33230948
8.
Temporal patterns and predictors of receiving no active treatment among older patients with acute myeloid leukemia in the United States: A population-level analysis.
Cancer;
125(23): 4241-4251, 2019 12 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31483484
9.
Underutilization of guideline-recommended supportive care among older adults with multiple myeloma in the United States.
Cancer;
125(22): 4084-4095, 2019 Nov 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-31381151
10.
Outcomes and Toxicities of Programmed Death-1 (PD-1) Inhibitors in Hodgkin Lymphoma Patients in the United States: A Real-World, Multicenter Retrospective Analysis.
Oncologist;
24(7): 955-962, 2019 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-30568021
11.
Cost-effectiveness of liposomal cytarabine/daunorubicin in patients with newly diagnosed acute myeloid leukemia.
Blood;
139(11): 1766-1770, 2022 03 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-35298594
12.
Impact of Hydroxyurea on Survival and Risk of Thrombosis Among Older Patients With Essential Thrombocythemia.
J Natl Compr Canc Netw;
17(3): 211-219, 2019 03 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30865915
13.
Physician Experience and Risk of Rituximab Discontinuation in Older Adults With Non-Hodgkin's Lymphoma.
J Natl Compr Canc Netw;
17(10): 1194-1202, 2019 10 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31590152
14.
Oncologist volume and outcomes in older adults diagnosed with diffuse large B cell lymphoma.
Cancer;
124(21): 4211-4220, 2018 11 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30216436
15.
R-CHOP versus dose-adjusted R-EPOCH in frontline management of primary mediastinal B-cell lymphoma: a multi-centre analysis.
Br J Haematol;
180(4): 534-544, 2018 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-29265182
16.
COVID-19 in patients with CLL: improved survival outcomes and update on management strategies.
Blood;
138(18): 1768-1773, 2021 11 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-34297826
17.
Treatment patterns and real-world effectiveness of rituximab maintenance in older patients with mantle cell lymphoma: a population-based analysis.
Haematologica;
108(8): 2218-2223, 2023 08 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36655436
18.
The changing face of adult posttransplant lymphoproliferative disorder: Changes in histology between 1999 and 2013.
Am J Hematol;
93(7): 874-881, 2018 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-29659047
19.
Peripheral Blasts in a Patient Receiving Chemotherapy.
JAMA;
330(16): 1581-1582, 2023 10 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-37801303
20.
When competition is not enough: leveraging US policies to curb oral anticancer drug costs.
Lancet Oncol;
23(7): 836-837, 2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35772451